A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants

An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Subjects

The primary objective of this study is to determine the pharmacokinetics (PK) and excretion of E7090 and its metabolites in healthy male participants. Also, to assess the safety and tolerability of a single dose of E7090 in healthy male participants.

Study Overview

• Status: Completed
• Conditions: Healthy Volunteers
• Intervention / Treatment: Drug: [14C]E7090

• Study Type: Interventional
• Enrollment (Actual): 8
• Phase: Phase 1

Contacts and Locations

Study Locations

• United Kingdom
  • Leeds, United Kingdom, LS2 9LH
    • Covance Clinical Research Unit

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 35 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

1. Non-smoking, healthy males, age greater than or equal to (>=) 35 years and less than or equal to (<=) 55 years old at the time of informed consent
2. Body Mass Index (BMI) of >=18 to <=32 kilogram per square meter (kg/m^2) at Screening
3. Provide written informed consent
4. Willing and able to comply with all aspects of the protocol
5. History of a minimum of 1 bowel movement per day

Exclusion Criteria:

1. Participant has participated in any clinical research study involving a radiolabeled investigational product within the 12 months prior to Day -1 (Baseline)
2. Participant has previously completed or withdrawn from this study or any other study investigating E7090 or previously received E7090
3. Participant has had exposure to significant diagnostic or therapeutic radiation (example: serial x-ray, computed tomography scan, barium meal) or has current employment in a job requiring radiation exposure monitoring within 12 months prior to Day -1

4. Participant has the following ocular disorders:

   1. Any previous history or current evidence of corneal disorder
   2. Any previous history or current evidence of active macular disorder (example: age-related macular degeneration, central serous chorioretinal disease)
5. Participants has a known history of clinically significant drug allergy at Screening or Baseline (Day -1)
6. Participants has a known history of food allergies or significant seasonal or perennial allergy
7. Participants is known to be human immunodeficiency virus positive at Screening
8. Participants has active viral hepatitis (B or C) as demonstrated by positive serology at Screening
9. Participant has a poor peripheral venous access, in the opinion of the investigator (or designee)
10. Participant received blood products within 2 months prior to Day -1, or donation of blood within 3 months prior to Screening, donation of plasma within 2 weeks prior to Screening, or donation of platelets from 6 weeks prior to Screening

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: E7090; Participants will receive 100 microcurie (μCi) of [14C]E7090 as a single 35 milligram (mg), capsule, orally on Day 1.	Drug: [14C]E7090; [14C]E7090, oral capsule.; Other Names: E7090

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
feu: Percentage of Administered Radioactive Dose of [14C]E7090 Excreted in Urine	Up to Day 57
Cumulative feu: Cumulative Percentage of Administered Radioactive Dose of [14C]E7090 Excreted in Urine From 0 to tlast Hours	Up to Day 57
fef: Percentage of Administered Radioactive Dose of [14C]E7090 Excreted in Feces	Up to Day 57
Cumulative fef: Cumulative Percentage of Administered Radioactive Dose of [14C]E7090 Excreted in Feces From 0 to tlast Hours	Up to Day 57
feu+ef: Percentage of Administered Radioactive Dose excreted of [14C]E7090 in Combined Excreta (Urine and Feces)	Up to Day 57
Cumulative feu+ef: Cumulative Percentage of Administered Radioactive Dose excreted of [14C]E7090 in Combined Excreta (Urine and Feces) From 0 to tlast Hours	Up to Day 57
Cmax: Maximum Observed Plasma Concentration for [14C]E7090, E7090 and its Metabolites	Day 1: 0-672 hours post-dose
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for [14C]E7090, E7090 and its Metabolites	Day 1: 0-672 hours post-dose
AUC(0-24h): Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Postdose for [14C]E7090, E7090 and its Metabolites	Day 1: 0-24 hours post-dose
AUC(0-t): Area Under the Concentration- time Curve From Time 0 to Time of Last Quantifiable Concentration for [14C]E7090, E7090 and its Metabolites	Day 1: 0-672 hours post-dose
AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for [14C]E7090, E7090 and its Metabolites	Day 1: 0-672 hours post-dose
T1/2: Terminal Elimination Phase Half-life for [14C]E7090, E7090 and its Metabolites	Day 1: 0-672 hours post-dose
CL/F: Apparent Total Body Clearance for E7090	Day 1: 0-672 hours post-dose
Vd/F: Apparent Volume of Distribution for E7090	Day 1: 0-672 hours post-dose
MPR AUC(0-inf): Metabolite to Parent Ratio For AUC(0-inf) of Metabolite to E7090, Corrected for Molecular Weights	Day 1: 0-672 hours post-dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Metabolic profile of E7090: Concentration of Metabolite of E7090 in Plasma, Urine, and Feces	Blood, urine and feces samples will be collected and analyzed to estimate the concentration of metabolite of E7090 by Liquid Chromatography/ multiple-stage Mass Spectroscopy method.	Up to Day 57
Number of Participants With Treatment-emergent Adverse Events (TEAEs)		Baseline up to Day 57
Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters Values		Baseline up to Day 29
Number of Participants With Clinically Significant Change From Baseline in Vital Signs Values		Baseline up to Day 29
Number of Participants With Clinically Significant Change From Baseline in 12 Lead Electrocardiogram (ECG) Findings		Baseline up to Day 29
Number of Participants With Any Suicidality Assessed Using Columbia-Suicide Severity Rating Scale (C-SSRS)	The C-SSRS is an interview-based rating scale to systematically assess any suicidality, any suicidal behavior, any suicidal ideation. Any suicidality: emergence of any suicidal ideation or suicidal behavior. Any suicidal behavior: when response is "yes" for any these questions- actual attempt to suicide, engaged in non-suicidal self-injurious behavior, interrupted attempt, aborted attempt, preparatory acts. Any suicidal ideation: when response is "yes" for any of these questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide. Number of participants with any suicidality will be reported for this outcome measure.	Baseline up to Day 29
Number of Participants With Clinically Significant Change From Baseline in Ophthalmic Examinations	Ophthalmic examinations includes visual acuity, funduscopy, optical coherence tomography, and slit-lamp examination.	Baseline up to Day 29
Number of Participants With Clinically Significant Change From Baseline in Physical Examinations		Baseline up to Day 29

Collaborators and Investigators

• Sponsor: Eisai Limited

Study record dates

Study Major Dates

• Study Start (Actual): September 9, 2020
• Primary Completion (Actual): October 21, 2020
• Study Completion (Actual): October 21, 2020

Study Registration Dates

• First Submitted: July 15, 2020
• First Submitted That Met QC Criteria: July 29, 2020
• First Posted (Actual): July 30, 2020

Study Record Updates

• Last Update Posted (Actual): February 4, 2021
• Last Update Submitted That Met QC Criteria: February 3, 2021
• Last Verified: July 1, 2020

More Information

Terms related to this study

• Keywords: Pharmacokinetics; Phase 1; Healthy Participants
• Other Study ID Numbers: E7090-E044-002; 2019-004957-10 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No